Keyphrases
Health Systems
100%
Percutaneous Coronary Intervention
63%
Mount Sinai
56%
COVID-19
55%
COVID-19 Patients
50%
Transforming Growth Factor-β
50%
Mobile Application
50%
ST-elevation Myocardial Infarction (STEMI)
50%
Aortic Stenosis
44%
Clinical Outcomes
36%
High Risk
35%
Mortality Risk
33%
Myocardial Infarction Patients
30%
Heart Failure
30%
Von Willebrand Disease
25%
Left Ventricular Assist Device
25%
Inferior Vena Cava Thrombosis
25%
Residual Platelet Reactivity
25%
Renal Cell Carcinoma
25%
Rapid Discrimination
25%
During Pregnancy
25%
Right Atrium
25%
Convalescent Plasma Therapy
25%
Comorbidity
25%
Review Topic
25%
Angiotensin-converting Enzyme 2 (ACE2)
25%
Type 1 Diabetes Mellitus (T1DM)
25%
Retrospective Analysis
25%
Placebo-controlled Randomized Trial
25%
Demographic Factors
25%
Heyde Syndrome
25%
Patients with Diabetes
25%
Relative Risk
25%
Renin-angiotensin System
25%
THEMIS
25%
Stable Coronary Artery Disease
25%
Chronic Kidney Disease
25%
Severe Coronavirus Disease 2019
25%
Blood Biomarkers
25%
Ticagrelor
25%
Valve Replacement
25%
Single Center
25%
Balloon Valvuloplasty
25%
Von Willebrand Factor Cleaving Protease
25%
ADAMTS13
25%
Aortic Valve Replacement
25%
Impella
25%
CYP2C19 Polymorphism
25%
Allele-specific
25%
Genotype
25%
Medicine and Dentistry
COVID-19
75%
Percutaneous Coronary Intervention
60%
Health System
50%
Severe Acute Respiratory Syndrome Coronavirus 2
37%
Infection
34%
Prevalence
33%
Coronary Artery Disease
30%
Randomized Controlled Trial
29%
Renin Angiotensin Aldosterone System
25%
Clear Cell Renal Cell Carcinoma
25%
Placebo
25%
Right Atrium
25%
Aortic Stenosis
25%
Angiotensin Converting Enzyme 2
25%
Transluminal Valvuloplasty
25%
Valve Replacement
25%
Von Willebrand Factor Cleaving Proteinase
25%
Thrombus
25%
Patient with Diabetes
25%
Sequela
25%
Biological Marker
25%
Aortic Valve Replacement
25%
Inferior Vena Cava
25%
Ticagrelor
25%
ST Segment Elevation Myocardial Infarction
25%
Tumor Thrombus
25%
Comorbidity
25%
Von Willebrand Factor
22%
Emergency Department
19%
Disease
19%
Aortic Valvuloplasty
13%
Cardiac Catheterization
10%
Cardiovascular System
10%
Severe Acute Respiratory Syndrome
10%
SARS Coronavirus
10%
Intensive Care Unit
10%
angiotensin[1-7]
10%
Myocardial Infarction
9%
Thromboembolism
8%
Lung
8%
Chi Square Test
8%
Antivirus Agent
8%
Retrospective Study
8%
Patient Population
8%
Acetylsalicylic Acid
7%
Lupus Anticoagulant
7%
Diabetes
6%
Major Bleeding
6%
Assisted Circulation
6%
Polymer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Aortic Stenosis
50%
Fibrinogen
50%
Cancer Growth Factor
50%
Disease
36%
SARS Coronavirus
35%
Coronary Artery Disease
30%
Congestive Heart Failure
30%
Heart Infarction
29%
Infection
28%
Randomized Controlled Trial
28%
Biological Marker
28%
Syndrome
28%
Diabetes Mellitus
27%
Von Willebrand Factor
26%
Renin
25%
Coronavirinae
25%
Chronic Kidney Failure
25%
Angiotensin
25%
Anemia
25%
Placebo
25%
Von Willebrand Factor Cleaving Proteinase
25%
Angiotensin Converting Enzyme 2
25%
ST Segment Elevation Myocardial Infarction
25%
Ticagrelor
25%
Comorbidity
25%
Bleeding
21%
Prevalence
20%
Renal Diabetes
20%
Retrospective Study
17%
Cause of Death
14%
Major Adverse Cardiac Event
12%
Adverse Event
12%
angiotensin[1-7]
10%
Severe Acute Respiratory Syndrome
10%
Polymer
9%
Acetylsalicylic Acid
8%
Antivirus Agent
7%
Gastrointestinal Hemorrhage
6%
Thromboembolism
5%
Asthma
5%
Virus Infection
5%
Receptor
5%
Clopidogrel
5%
Anti-Inflammatory Drug
5%
Inflammation
5%
Mineralocorticoid Antagonist
5%
Renin-Angiotensin System Inhibitor
5%
Atrial Fibrillation
5%
Dipeptidyl Carboxypeptidase Inhibitor
5%
Angiotensin Receptor Antagonist
5%